Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial

BACKGROUND: The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms to severe complications, including acute respiratory distress syndrome. In this syndrome, inflammatory cytokines are released after activation of the inflammatory cascade, with the predominant role of interleukin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dastan, Farzaneh, Saffaei, Ali, Haseli, Sara, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Abedini, Atefeh, Kiani, Arda, Seifi, Sharareh, Jammati, Hamidreza, Hashemian, Seyed Mohammad Reza, Pourabdollah Toutkaboni, Mihan, Eslaminejad, Alireza, Heshmatnia, Jalal, Sadeghi, Mohsen, Nadji, Seyed Alireza, Dastan, Alireza, Baghaei, Parvaneh, Varahram, Mohammad, Yousefian, Sahar, Salamzadeh, Jamshid, Tabarsi, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402206/
https://www.ncbi.nlm.nih.gov/pubmed/32889241
http://dx.doi.org/10.1016/j.intimp.2020.106869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402206/
https://www.ncbi.nlm.nih.gov/pubmed/32889241
http://dx.doi.org/10.1016/j.intimp.2020.106869

Ejemplares similares